emtricitabine and HIV
emtricitabine has been researched along with HIV in 72 studies
*HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. [MeSH]
Research
Studies (72)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (6.94) | 18.2507 |
| 2000's | 7 (9.72) | 29.6817 |
| 2010's | 39 (54.17) | 24.3611 |
| 2020's | 21 (29.17) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Cheng, YC; Dutschman, GE; Gullen, E; Lin, TS; Liu, MC; Luo, MZ; Zhu, YL | 1 |
| Bazzi, R; Roa, PE | 1 |
| Aidara, M; Alleyo, A; Diallo, K; Manga, NM; Wembulua, BS | 1 |
| Bamford, L; Burkholder, GA; Cachay, ER; Christopoulos, K; Crane, HM; Delaney, JAC; Eron, JJ; Gravett, RM; Jacobson, JM; Keruly, J; Kitahata, MM; Ma, J; Martin, J; Mayer, KH; Moore, RD; Nance, RM; Napravnik, S; Saag, MS; Whitney, BM | 1 |
| Adeyeye, A; Agyei, Y; Anderson, PL; Bushman, LR; Chau, G; Cohen, MS; Cummings, V; Delany-Moretlwe, S; Eshleman, SH; Farrior, J; Fogel, JM; Ford, S; Haines, CD; Hanscom, B; Hendrix, CW; Hosseinipour, M; Hughes, JP; Hunidzarira, P; Kofron, R; Marzinke, MA; Mathew, CA; Mellors, J; Mpendo, J; Nair, G; Persaud, D; Petropoulos, C; Piwowar-Manning, E; Richardson, P; Rinehart, A; Rooney, JF; Spooner, E; St Clair, M; Sullivan, P | 1 |
| Anderson, P; Baeten, JM; Celum, CL; Choopanya, K; Garcia-Cremades, M; Glidden, DV; Grant, R; Hendrix, CW; Jarlsberg, L; Jayachandran, P; Marrazzo, J; Martin, M; Savic, RM; Vanichseni, S; Vučićević, K | 1 |
| Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A | 1 |
| Berry, E; Covaci, A; Gys, C; Heytens, L; Jacobs, W; Lambert, W; Meskal, A; Mortelé, O; Neels, H; Schouwers, S; Van Hemeldonck, E; van Nuijs, ALN; van Rafelghem, B | 1 |
| Barham, L; Dzinamarira, T; Mhango, M; Moyo, E; Musuka, G | 1 |
| Fan, L; Gao, L; Hu, Y; Huang, R; Li, L; Ma, P; Qiu, C; Wu, Y; Yu, A; Zhang, D | 1 |
| Anderson, PL; Glidden, DV; Marzinke, MA | 1 |
| Del Amo, J | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Ishikawa, K; Kawai, F; Mori, N | 1 |
| Anderson, PL; Bekker, LG; Boily, MC; Celum, CL; Delany-Moretlwe, S; Dimitrov, D; Donnell, DJ; Mgodi, NM; Mitchell, KM; Moore, M; Stansfield, S | 1 |
| Beste, LA; Garner, W; Maier, MM; Ohl, ME; Van Epps, P; Wilson, BM | 1 |
| Atukunda, M; Ayieko, J; Balzer, LB; Black, D; Brown, LB; Bukusi, EA; Camlin, CS; Chamie, G; Charlebois, ED; Clark, TD; Cohen, CR; Gandhi, M; Havlir, DV; Jain, V; Kabami, J; Kamya, MR; Koss, CA; Kwarisiima, D; Marquez, C; Mwangwa, F; Mwinike, Y; Olilo, W; Owaraganise, A; Peng, J; Petersen, ML; Rooney, JF; Ruel, TD; Sang, N; Zhang, K | 1 |
| Anderson, PL; Defechereux, P; Gandhi, M; Grant, RM; Jee, K; Johannessen, D; Kearney, MF; Kuncze, K; Lowery, B; McDonald, C; McFarlane, JR; Okochi, H; Phung, N; Shuford, JA; Smith, DK; Spindler, J; Spinelli, MA | 1 |
| Baeten, JM; Berard, AR; Birse, K; Burgener, A; Calienes, FL; Cameron, MJ; Cartwright, M; Collier, AC; Cranston, RD; Curlin, ME; Golden, JB; Hladik, F; Holtz, TH; Hughes, SM; Irungu, E; Katabira, E; Lama, JR; Levy, CN; Lingappa, JR; Mackelprang, R; McElrath, MJ; McGowan, I; Mugo, N; Muwonge, T; Noël-Romas, L; Pandey, U; Richardson, B; Stekler, JD; Stevens, CE; Vojtech, L | 1 |
| Patel, RR; Rowan, SE; Schneider, JA; Smith, DK | 1 |
| Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
| Baeten, JM; Donnell, D; Gandhi, M; Glidden, DV; Hendrix, C; Marzinke, M; Mugo, N; Mujugira, A; Rodrigues, WC; Spinelli, MA; Stalter, RM; Vincent, M; Wang, G | 1 |
| Chang, SF; Chang, SY; Hsiao, YY; Huang, YC; Hung, CC; Kuo, CH; Lee, YL; Lin, YT; Luo, YZ | 1 |
| Bennett, M; Coca, SG; Defechereux, P; Gandhi, M; Glidden, DV; Grant, RM; Jotwani, V; Liu, A; Mehrotra, M; Parikh, CR; Scherzer, R; Shlipak, MG | 1 |
| Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N | 1 |
| Gordon, CM; Havens, PL; Kapogiannis, BG; Long, D; Mulligan, K; Price, G; Schuster, GU; Stephensen, CB; Wilson, CM | 1 |
| Bogner, JR | 1 |
| Naing, C; Poovorawan, Y; Tong, KS | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Bachman, S; Cong, ME; García-Lerma, JG; Hanson, DL; Heneine, W; Mitchell, J; Sweeney, E | 1 |
| Brooks, JT; Chirwa, LI; Henderson, FL; Johnson, JA; Li, JF; Matlhaba, O; Niska, RW; Paxton, LA; Rose, CE; Segolodi, TM; Thigpen, MC | 1 |
| Ayala-Sims, VA; Fulco, PP | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| Debyser, Z; Schrijvers, R | 1 |
| Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K | 1 |
| Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K | 1 |
| Amiel, C; Chas, J; Guessant, S; Hamidi, M; Kherallah, K; Lebrette, MG; Lependeven, C; Pialoux, G; Schneider, V | 1 |
| Calvez, V; Desire, N; Girard, PM; Katlama, C; Marcelin, AG; Mercier-Darty, M; Morand-Joubert, L; Rodriguez, C; Todesco, E; Wirden, M | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Ajose, O; Beanland, RL; Calmy, A; Doherty, M; Ford, N; Irvine, C; Mayer, KH; Rapparini, C; Shubber, Z; Vitoria, M | 1 |
| Baeten, JM; Celum, C; Donnell, D; Hendrix, CW; Lehman, DA; Marzinke, MA; Matsen, FA; McCoy, CO; Mugo, N; Thomas, KK; Warth, C; Weis, JF | 1 |
| Ebell, MH | 1 |
| Anderson, PL; Bushman, LR; Campbell, K; Castillo-Mancilla, J; Coleman, S; Gardner, EM; Glidden, DV; Grant, R; Hosek, S; Liu, A; MaWhinney, S; McAllister, K; Seifert, S; Wilson, CM; Zheng, JH | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Castagna, A; Chiappetta, S; Galli, L; Lazzarin, A; Nozza, S; Poli, A; Ripa, M; Rovelli, C; Spagnuolo, V; Tambussi, G | 1 |
| Anderson, PL; Bushman, LR; Castillo-Mancilla, JR; Chen, X; Kiser, JJ; MaWhinney, S; Seifert, SM; Zheng, JH | 1 |
| Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
| Fiorante, S; Pulido, F | 1 |
| Boucher, CA; van de Vijver, DA | 1 |
| Murphy, B; Romanelli, F | 1 |
| Amico, KR; Anderson, PL; Bekker, LG; Buchbinder, SP; Burns, DN; Bushman, LR; Casapía, M; Chariyalertsak, S; Defechereux, P; Fernández, T; Ganoza, C; Glidden, DV; Goicochea, P; Grant, RM; Guanira-Carranza, JV; Hance, RJ; Jaffe, HS; Kallás, EG; Lama, JR; Lee, J; Liu, AY; Martinez, AI; Mayer, KH; McConnell, JJ; McMahan, V; Montoya-Herrera, O; Mulligan, K; Postle, B; Ramirez-Cardich, ME; Rooney, JF; Schechter, M; Vargas, L; Veloso, VG; Wang, F; Zheng, JH | 1 |
| Aung, W; Cong, ME; Dobard, C; Garcia-Lerma, JG; Heneine, W; Mitchell, J; Sharma, S; Youngpairoj, AS | 1 |
| Aung, W; Cong, ME; Dobard, C; García-Lerma, JG; Hanson, DL; Hendry, RM; Heneine, W; Mitchell, J; Sweeney, E; Youngpairoj, AS; Zheng, Q | 1 |
| Cong, ME; Curtis, KA; García-Lerma, JG; Hanson, D; Heneine, W; Kennedy, MS; Luckay, A; Owen, SM; Smith, J; Youngpairoj, AS; Zheng, Q | 1 |
| Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Nelson, MR; Waters, L | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Jenny-Avital, ER | 1 |
| Aguilar, I; Hidalgo, A; Palacios, R; Santos, J | 1 |
| Ananworanich, J; Chetchotisakd, P; Hirschel, B; Jupimai, T; Klinbuayam, W; Mahanontharit, A; Nüesch, R; Prasithsirikul, W; Ruxrungtham, K; Srasuebkul, P | 1 |
| Frick, LW; Lambe, CU; Nelson, DJ; St John, L; Taylor, LC | 1 |
| Farrant, RD; Frick, LW; Lindon, JC; Sanderson, PN; Shockcor, JP; Sweatman, BC; Wurm, RM | 1 |
| Cannon, D; Furman, PA; Lloyd, RM; Mathis, R; McMillan, A; Peck, A; Schinazi, RF; Sommadossi, JP; St Clair, M; Wilson, J | 1 |
| Peck, A; Schinazi, RF; Sommadossi, JP | 1 |
Reviews
14 review(s) available for emtricitabine and HIV
| Article | Year |
|---|---|
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review.
Topics: Anti-HIV Agents; Cerebral Infarction; Drug Combinations; Emtricitabine; Herpesvirus 3, Human; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Viral Load | 2023 |
Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Drug Prescriptions; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Practice Patterns, Physicians'; Pre-Exposure Prophylaxis; Safe Sex; Tenofovir; United States | 2021 |
[HIV - Innovation of diagnosis and treatment during the last decade].
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; HIV Integrase Inhibitors; Humans | 2018 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Network Meta-Analysis; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Tenofovir; World Health Organization | 2015 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
[Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cohort Studies; Deoxycytidine; Diabetic Nephropathies; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Kidney Diseases; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Tenofovir; Treatment Outcome | 2008 |
The risk of HIV drug resistance following implementation of pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Risk Assessment; Tenofovir; Viremia | 2010 |
Systemic preexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adenine; Animals; Anti-HIV Agents; Antiviral Agents; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Occupational Exposure; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Tenofovir | 2010 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
New drugs.
Topics: Anti-HIV Agents; Benzophenones; Cytidine Triphosphate; Darunavir; Deoxycytidine; Emtricitabine; HIV; HIV Fusion Inhibitors; HIV Reverse Transcriptase; Humans; Imidazoles; Nitriles; Protease Inhibitors; Pyridazines; Pyridines; Pyrimidines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Sulfur Compounds; Zalcitabine | 2005 |
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors | 2006 |
Trials
14 trial(s) available for emtricitabine and HIV
| Article | Year |
|---|---|
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
Topics: Anti-HIV Agents; Diketopiperazines; DNA-Directed RNA Polymerases; Emtricitabine; Female; HIV; HIV Infections; Humans; Nucleosides; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
Topics: Adult; Albuminuria; Alpha-Globulins; Anti-HIV Agents; Biomarkers; Cross-Sectional Studies; Emtricitabine; Female; Glomerular Filtration Rate; HIV; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Male; Pre-Exposure Prophylaxis; Proteinuria; Tenofovir; Transgender Persons; Urine; Young Adult | 2018 |
Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Bone and Bones; Bone Density; Cohort Studies; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Parathyroid Hormone; Pre-Exposure Prophylaxis; Tenofovir; Vitamin D; Vitamin D Deficiency; White People; Young Adult | 2018 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Quinolones; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir; Thiazoles; Viral Load | 2014 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Family Characteristics; Female; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Male; Mutation, Missense; Placebos; Pre-Exposure Prophylaxis; RNA, Viral; Sequence Analysis, DNA; Tenofovir | 2016 |
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Case-Control Studies; Dried Blood Spot Testing; Drug Administration Schedule; Emtricitabine; Female; Half-Life; HIV; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Tenofovir | 2016 |
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Follow-Up Studies; HIV; HIV Antibodies; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Organophosphonates; Patient Compliance; RNA, Viral; Tenofovir; Transsexualism; Young Adult | 2010 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
Topics: Adenine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Male; Organophosphonates; Tenofovir; Thailand; Transaminases; Treatment Outcome; Viral Load | 2008 |
Hplc-nmr identification of the human urinary metabolites of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analogue active against human immunodeficiency virus (HIV).
Topics: Antiviral Agents; Biotransformation; Chromatography, High Pressure Liquid; Emtricitabine; Glucuronates; HIV; Humans; Magnetic Resonance Spectroscopy; Spectrophotometry, Ultraviolet; Stereoisomerism; Sulfoxides; Zalcitabine | 1996 |
Other Studies
44 other study(ies) available for emtricitabine and HIV
| Article | Year |
|---|---|
Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human
Topics: Antiviral Agents; Drug Design; Hepatitis B virus; HIV; Humans; Zalcitabine | 1996 |
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Male; Oxazines; Pancreatic Neoplasms; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2022 |
Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.
Topics: Emtricitabine; Female; HIV; HIV Infections; Humans; Humeral Head; Lopinavir; Middle Aged; Osteonecrosis; Ritonavir; Tenofovir | 2021 |
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
Topics: Acquired Immunodeficiency Syndrome; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Tenofovir; United States | 2022 |
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Data Analysis; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2022 |
Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Topics: Absorbable Implants; Alanine; Animals; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Macaca; Necrosis; Simian Immunodeficiency Virus; Tenofovir | 2022 |
Overdose of the HIV Medicine Genvoya® in Two Auto-Intoxications.
Topics: Anti-HIV Agents; Drug Combinations; Drug Overdose; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV; HIV Infections; Humans | 2023 |
Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 - 2023).
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Emtricitabine; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Namibia; Pre-Exposure Prophylaxis; Public Health; Public Sector; Tenofovir | 2022 |
Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir | 2022 |
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir | 2023 |
Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019.
Topics: Anti-HIV Agents; COVID-19; Emtricitabine; HIV; HIV Infections; Humans; Tenofovir; United States | 2023 |
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2023 |
Brief Report: Incidence of HIV in a Nationwide Cohort Receiving Pre-exposure Prophylaxis for HIV Prevention.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV; HIV Infections; Humans; Incidence; Male; Medication Adherence; Middle Aged; Mutation; Phosphorous Acids; Pre-Exposure Prophylaxis; Retrospective Studies; United States; United States Department of Veterans Affairs; Young Adult | 2019 |
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study.
Topics: Adolescent; Adult; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Kenya; Male; Mass Screening; Medication Adherence; Middle Aged; Pre-Exposure Prophylaxis; Rural Population; Sex Workers; Tenofovir; Uganda; Young Adult | 2020 |
Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; Humans; Medication Adherence; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Seroconversion; Tenofovir | 2021 |
Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; Gastrointestinal Microbiome; Gene Expression; HIV; HIV Infections; Humans; Interferon Type I; Male; Middle Aged; Pharmaceutical Preparations; Pre-Exposure Prophylaxis; Tenofovir; Transcriptome | 2020 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Urine Tenofovir Levels Measured Using a Novel Immunoassay Predict Human Immunodeficiency Virus Protection.
Topics: Anti-HIV Agents; Emtricitabine; HIV; HIV Infections; Humans; Immunoassay; Medication Adherence; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Male; Mutation; Pre-Exposure Prophylaxis; Tenofovir | 2021 |
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle Aged; Pre-Exposure Prophylaxis; Tenofovir; Young Adult | 2018 |
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome; Vagina | 2019 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
Prophylactic efficacy of oral emtricitabine and tenofovir disoproxil fumarate combination therapy against a tenofovir-resistant simian/human immunodeficiency virus containing the K65R mutation in macaques.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Deoxycytidine; Disease Transmission, Infectious; Drug Resistance, Viral; Emtricitabine; HIV; Macaca; Mutation, Missense; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome | 2013 |
CD4(+) cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis.
Topics: Adenine; Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Chemoprevention; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Heterosexuality; HIV; HIV Infections; Humans; Organophosphonates; Plasma; Post-Exposure Prophylaxis; Tenofovir; Viral Load | 2014 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Organophosphonates; Powders; Quinolones; Tablets; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thiazoles | 2014 |
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir | 2014 |
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Plasma; Tenofovir; Treatment Failure | 2015 |
Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Homosexuality, Male; Humans; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Emtricitabine; HIV; HIV Infections; Humans; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Topics: Adult; Anti-HIV Agents; Computer Simulation; Deoxyadenine Nucleotides; Deoxycytosine Nucleotides; Diphosphates; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Polyphosphates; Prospective Studies; Tenofovir; Young Adult | 2016 |
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Antibodies; HIV Infections; Humans; Infection Control; Liver Transplantation; Mice; Occupational Exposure; Organophosphonates; Organophosphorus Compounds; Tenofovir; Thymus Gland; Transplantation Chimera | 2010 |
Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Resistance, Viral; Emtricitabine; HIV; Humans; Macaca; Mutation; Organophosphonates; Recombination, Genetic; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Virus Cultivation | 2011 |
Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.
Topics: Animals; Antiviral Agents; Cell Line; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; Humans; Macaca mulatta; Mutation; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus | 2011 |
Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Deoxycytidine; Drug Combinations; Emtricitabine; HIV; HIV Antibodies; Human Immunodeficiency Virus Proteins; Macaca mulatta; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Viral Load | 2011 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; France; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Retrospective Studies; RNA, Viral; Selection, Genetic; Tenofovir; Treatment Failure; Viral Load | 2012 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus.
Topics: Administration, Oral; Animals; Antiviral Agents; Biological Availability; Emtricitabine; Hepatitis B virus; HIV; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Species Specificity; Zalcitabine | 1994 |
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
Topics: Antiviral Agents; Emtricitabine; HIV; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stereoisomerism; Zalcitabine; Zidovudine | 1992 |
Substrate specificity of Escherichia coli thymidine phosphorylase for pyrimidine nucleosides with anti-human immunodeficiency virus activity.
Topics: Antiviral Agents; Biological Availability; Deoxyuridine; Dideoxynucleosides; Emtricitabine; Escherichia coli; HIV; Pyrimidine Nucleosides; Stavudine; Substrate Specificity; Thymidine Phosphorylase; Zalcitabine | 1992 |